Page 349 - 2022_01-Haematologica-web
P. 349
Letters to the Editor
cell division which would be expected to increase IE. However, it may also be acting in other ways, such as increasing stress erythropoiesis in the bone marrow niche of SCD patients. IoIE may be useful to monitor the effects of transfusion and HU in SCD, and to evaluate the effects of novel therapies.
John Brewin,1,2* Sara El Hoss,1* John Strouboulis1 and David Rees1,2
1Molecular Haematology, Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King’s College London and 2Department of Haematological Medicine, King’s College Hospital, London, UK
*JB and SEH contributed equally as co-first authors. Correspondence:
SARA EL HOSS - sara.el_hoss@kcl.ac.uk doi:10.3324/haematol.2021.279623
Received: July 12, 2021.
Accepted: October 11, 2021. Pre-published: October 21, 2021. Disclosures: no conflicts of interest to disclose.
Contributions: JB collected data, analysed, wrote and edited the manuscript; SEH analysed data, wrote and edited the manuscript; JS contributed to the design of the study, interpretation of data and wrote and edited the manuscript; DR designed the study, wrote and edited the manuscript.
Acknowledgments: we would like to thank the patients involved in this study and the medical staff of KCH for taking care of the patients. We also thank the members of the Molecular Haematology research lab at King’s College London for their support during this work.
References
1. Orkin SH. Diversification of haematopoietic stem cells to specific lineages. Nat Rev Genet. 2000:1(1):57-64.
2. Ribeil JA, Arlet JB, Dussiot M, et al. Ineffective erythropoiesis in beta-thalassemia. ScientificWorldJournal. 2013;2013:394295.
3. Hasegawa S, Rodgers GP, Dwyer N, et al. Sickling of nucleated ery-
throid precursors from patients with sickle cell anemia. Exp
Hematol. 1998;26(4):314-319.
4. Wu CJ, Krishnamurti L, Kutok JL, et al. Evidence for ineffective ery-
thropoiesis in severe sickle cell disease. Blood. 2005;106(10):3639-
3645.
5. El Hoss S, Cochet S, Godard A, et al. Fetal hemoglobin rescues inef-
fective erythropoiesis in sickle cell disease. Haematologica. 2021;
106(10):2707-2719.
6. Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA. Intact
transferrin receptors in human plasma and their relation to erythro-
poiesis. Blood. 1990;75(1):102-107.
7.Lulla RR, Thompson AA, Liem RI. Elevated soluble transferrin
receptor levels reflect increased erythropoietic drive rather than iron deficiency in pediatric sickle cell disease. Pediatr Blood Cancer. 2010; 55(1):141-144.
8. Al-Saqladi AW, Bin-Gadeem HA, Brabin BJ. Utility of plasma trans- ferrin receptor, ferritin and inflammatory markers in children with sickle cell disease. Paediatr Int Child Health. 2012;32(1):27-34.
9. Hebbel RP. Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol. 2011;86(2):123-154.
10. Allen J, Backstrom KR, Cooper JA, et al. Measurement of soluble transferrin receptor in serum of healthy adults. Clin Chem. 1998; 44(1):35-39.
11. Rees DC, Porter JB, Clegg JB, Weatherall DJ. Why are hemoglobin F levels increased in HbE/beta thalassemia? Blood. 1999;94(9):3199- 3204
12. Brewin JN, Rooks H, Gardner K, et al. Genome wide association study of silent cerebral infarction in sickle cell disease (HbSS and HbSC). Haematologica. 2021;106(6):1770-1773.
13. Rana S, Houston PE, Wang WC, et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics. 2014;134(3):465- 472.
14. Schuchard SB, Lissick JR, Nickel A, et al. Hydroxyurea use in young infants with sickle cell disease. Pediatr Blood Cancer. 2019; 66(7):e27650.
15. Park SY, Matte A, Jung Y, et al. Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfu- sion. Blood. 2020;135(23):2071-2084.
16.Ballas SK. The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease. Mediterr J Hematol Infect Dis. 2020;12(1):e2020010.
17. Pule GD, Mowla S, Novitzky N, Wiysonge CS, Wonkam A. A sys- tematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Rev Hematol. 2015;8(5):669-679.
haematologica | 2022; 107(1)
341
